Nisa Investment Advisors Boosts Stake in Eli Lilly

Firm increases holdings in pharmaceutical giant by 6.8% in Q4

Apr. 3, 2026 at 9:37am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex arrangement of industrial gears, pistons, and other heavy machinery in muted tones of steel grey, bronze, and black, conceptually representing the complex financial infrastructure and institutional power of the pharmaceutical industry.Institutional investors closely monitor the financial machinery powering pharmaceutical giants like Eli Lilly, adjusting their holdings to capitalize on industry trends.Indianapolis Today

Nisa Investment Advisors LLC, a major institutional investor, increased its stake in Eli Lilly and Company (NYSE: LLY) by 6.8% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 225,853 shares of the pharmaceutical company's stock, valued at $242.7 million.

Why it matters

Eli Lilly is one of the world's largest and most influential pharmaceutical companies, with a diverse portfolio of blockbuster drugs. Institutional investors closely monitor and adjust their holdings in Lilly, as the stock's performance is seen as a bellwether for the broader healthcare sector.

The details

Nisa Investment Advisors, an investment management firm based in New York, added 14,439 shares of Eli Lilly to its portfolio during the fourth quarter. This increased the firm's total position in Lilly to 225,853 shares, or 3.4% of its overall holdings. The move comes as Lilly has seen its stock price rise steadily in recent quarters on the back of strong sales of key drugs like Trulicity, Taltz, and Verzenio.

  • Nisa Investment Advisors filed its Q4 2025 holdings disclosure with the SEC on April 3, 2026.
  • The firm increased its Eli Lilly stake during the three-month period ending December 31, 2025.

The players

Nisa Investment Advisors LLC

A New York-based investment management firm that oversees over $50 billion in assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative drug portfolio including diabetes, immunology, and oncology treatments.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Eli Lilly's upcoming quarterly earnings report to see if the company can maintain its strong momentum and justify the confidence shown by major institutional holders like Nisa Investment Advisors.

The takeaway

Eli Lilly's inclusion in the portfolios of top-tier investment firms underscores the company's status as a blue-chip healthcare stock. The increased stake by Nisa Investment Advisors signals that Wall Street remains bullish on Lilly's ability to drive shareholder value through its diverse drug pipeline and market-leading positions.